Combination therapy for advanced liver cancer
Part of Cancer clinical trials.
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that cannot be surgically removed and it hasn't spread outside the liver.
- You are between 18 and 80 years old.
- Your liver function is good (Child-Pugh class A) and you are in generally good health (ECOG 0 or 1).
- You have not had prior systemic therapy or Y90 treatment for your cancer.
- You do not have active autoimmune disease or a history of chronic autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—durvalumab, tremelimumab, and zanzalintinib—along with Y-90 radioembolization (a procedure that delivers radiation directly to liver tumors) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can help shrink tumors and improve outcomes.
This study tests whether a targeted radiation treatment called Y-90 segmentectomy can shrink liver tumors. It is for people with one to three small liver tumors that cannot be removed by surgery or destroyed by heat or cold (ablation).
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.